LinkedIn Google+ Twitter Facebook

ROS1 Testing

The ROS1 Biomarker provides enhanced molecular information for the treatment of NSCLC patients.

Caris Target Now® evidence-based molecular profiling service now offers ROS1 testing by FISH for Non-Small Cell Lung Cancer (NSCLC) patients. Both Caris Target Now Select and Caris Target Now Comprehensive NSCLC profiles will feature ROS1. The addition of ROS1 provides oncologists further molecular intelligence to make more informed treatment decisions.

ROS1: receptor tyrosine kinase and novel oncogenic driver in NSCLC

  • NSCLC patients with ROS1 translocation have shown positive response to crizotinib in limited clinical studies.1,2,3
  • ROS1 rearrangement occurs in 1-2% of NSCLC patients, or approximately 3,000-4,000 new patients in the United States each year.1,2
  • ROS1 rearrangement is predominantly seen in younger, never-smokers with adenocarcinoma.1
  • ROS1 translocations have been discovered in other tumors, including cholangiocarcinoma.4 It was first discovered in glioblastoma cell line U118MG.3 Additional studies are currently ongoing.

Caris Target Now Select is a focused tumor profiling service for On-Compendium therapeutic associations. Caris Target Now Comprehensive is a broad tumor profiling service for On-and Off-Compendium therapeutic associations. See the NSCLC profile menu for Caris Target Now Select and Comprehensive and all other Caris Target Now profile menus.

Learn more about treatments associated with specific biomarkers at CarisTargetNow.com, a complete resource for physicians to explore the application of cutting-edge cancer research to real world cancer treatment today.

Learn more about ordering and using Caris Target Now for your patients.

Or request a call from a Caris Target Now representative.

(1) ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers. Kristin Bergethon, et al. J Clin Oncol. 2012 Mar 10;30(8):863-70. Epub 2012 Jan 3.

(2) Identifying and targeting ROS1 gene fusions in NSCLC, Davies KD et al. 2012. Clin Can Res. 18:4570-4579.

(3) Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene arrangement. J Clin Oncol 30 (abstr 7508).

(4) Gu TL et al 2011 Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma, Shaw AT et al. 2012. PLoS One 6(1):e15640.